Newly-released Brachytherapy Market analysis report by Future Market Insights shows that global sales of the Brachytherapy Market in 2021 were held at US$ 892.9 million. With a CAGR of 8.3% from 2022 to 2032, the market is projected to reach a valuation of US$ 2.1 Bn by 2032. Applicators and Afterloaders are expected to be the highest revenue-generating segment, projected to grow at a CAGR of over 8.6% from 2022 to 2032.
| Attribute | Details |
|---|---|
| Global Brachytherapy Market (2022) | US$ 960.1 million |
| Global Brachytherapy Market (2032) | US$ 2.1 billion |
| Global Brachytherapy Market CAGR (2022 to 2032) | 8.3% |
| USA Brachytherapy Market CAGR (2022 to 2032) | 9% |
| Key Companies Profiled |
|
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
As per the Brachytherapy Market research by Future Market Insights - a market research and competitive intelligence provider, historically, from 2017 to 2021, the market value of Brachytherapy increased at around 7.2% CAGR.
During the projected period, the market is likely to develop due to rising cancer incidences, and technical improvements in brachytherapy. The variety of imaging techniques available, many of which can be utilized in real-time, has substantially extended the brachytherapy options. Ultrasound, Power Doppler imaging, positron emission tomography, and magnetic resonance imaging techniques are some of the techniques of brachytherapy.
As per the American Cancer Society, the number of new cancer cases globally is anticipated to reach 21.6 million by 2030, with more than 13 million cancer fatalities. According to the reports presented by WHO, cancer claimed the lives of around 10 million people in 2020. Breast cancer is also one of the most frequent cancers, with an estimated 2.26 million new cases in 2020.
Radiation treatment can be used to treat cancer in three ways: preventive, palliative, and curative. It can also be used on its own or in combination with other therapies including surgery, immunotherapy, and chemotherapy. Radiation's wide range of applications has raised its appeal among doctors. The most recent breakthroughs in radiation treatment enable a high dosage to be delivered to the target location while causing minimal harm to neighboring healthy tissues. This has increased the possibility of localized tumor management and improved cure rates, leading to an increase in the demand for radiation treatment.
Advances in the healthcare IT industry, expanding healthcare infrastructure, increased public-private partnerships, investments in cancer treatment, and rising demand for advanced care solutions are driving the market expansion.
Radiation treatment is constantly changing and advancing owing to the advancement of groundbreaking technologies. People are being educated about cancer and its treatments through new initiatives and awareness activities. For example, on 7 April 2022, also regarded as World Health Day, as per the strategy of WHO, the International Agency for cancer and research. Alongside, the Union for International Cancer Control and African Cancer Registry Network launched a publication to commemorate the occasion. The report presents the effort dedicated to the annihilation of cervical cancer in African countries.
Principal Consultant
In 2021, North America held the largest share of the global Brachytherapy Market. It accounted for over 35% of the global revenue derived from Brachytherapy. The surge is being fuelled by rising cancer rates combined with an aging population. Some of the key factors for regional market expansion are government support for the healthcare sector's development, a high level of cancer awareness, easy access to high-quality medical facilities, and advantageous reimbursement policies.
The growing number of cancer-care product advancements is assisting in the reduction of cancer-related mortality in North America. For example, as per the report published by the American Cancer Society, to overcome treatment resistance in cancers, researchers used a DNA origami/trojan approach. Also, techniques like self-eradication of cancer during meiosis or electro-permeabilizing the cancer cell membrane are also developed in America.
The United States is expected to account for the highest market of US$ 850.1 million by 2032. The market in the country is expected to register an absolute dollar opportunity of US$ 486 million and a projected CAGR of 9%. Due to many variables such as Research and Development (R&D) spending, high healthcare expenditures, the existence of significant companies, and the growing number of cancer patients, the United States is the largest market for brachytherapy.
AngioDynamics, Inc., Hologic, Inc., Isoray, Inc., and Sun Nuclear Corp. are among the leading companies operating in the USA brachytherapy market. To stay competitive in the market, players are using different strategies such as mergers and acquisitions, and collaborations to significantly contribute to market growth.
The brachytherapy market in the United Kingdom is projected to reach a valuation of US$ 83 million by 2032. Growing at a CAGR of 8.1%, the market in the country is expected to gross an absolute dollar opportunity of around US$ 45 million from 2022 to 2032.
In Japan, the market for brachytherapy is projected to garner US$ 71.4 million by 2032. During the forecast period, the market is expected to garner an absolute dollar opportunity of US$ 37 million, registering an absolute dollar opportunity of US$ 37 million.
The market in South Korea is expected to reach US$ 31 million by 2032 growing at a CAGR of 5.7% during the forecast period. From 2022 to 2032, the market is expected to register an absolute dollar opportunity of US$ 13.3 million.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The market revenue through Applicators and Afterloaders is expected to grow at a CAGR of 8.6% during the projection period. Because they are more efficient and are utilized for patient guidance across the cancer care continuum, this therapy plays a crucial role in cancer treatment. Increased investment in cancer research and development also contributes to rising demand for the therapy.
The market revenue through the Breast Cancer application is forecasted to grow at the highest CAGR from 2022 to 2032. This is mostly due to the rising incidence of breast cancer globally. Breast cancer has affected 2.5 million people worldwide in 2020, with 690,000 fatalities. Breast cancer has affected almost 8 million women during the period between 2016 to 20, making it the most common disease in the world.
The most frequent type of brachytherapy for breast cancer patients is intracavitary brachytherapy. In this method, a radioactive substance-containing device is implanted into the body and remains there until the therapy is finished. Furthermore, increased government initiatives to raise awareness and technical breakthroughs in minimally invasive surgical treatments contribute to the market's growth.
HDR (High-Dose Rate) Brachytherapy commanded the largest revenue as well as a CAGR of nearly 8.3%, during the forecast period. The reason pertains to the advantages it provides to cancer patients. HDR brachytherapy is a type of radiation therapy in which a large dose of radiation is delivered directly to the prostate. This implies that neighboring healthy tissue receives a low dosage of radiation and is less likely to be harmed or produce negative effects.
HDR brachytherapy can be used to treat a wide range of illnesses, including delivering accurate radiation to cancerous tumors while preventing radiation damage to surrounding tissue, instead of the five to seven weeks that regular radiation usually takes.
Some of the key players in the brachytherapy market include Eckert and Ziegler Group, Isoray Inc., Elekta AB, Theragenics Corp., Becton, Dickinson and Co., Varian Medical Systems Inc., iCAD Inc., CIVCO Medical Solutions, Sun Nuclear Corp., Huiheng Medical Inc., AngioDynamics Inc., and Hologic, Inc.
Some of the recent developments of key Brachytherapy providers are as follows:
Similarly, recent developments related to companies in the Brachytherapy market have been tracked by the team at Future Market Insights, which are available in the full report.
The global Brachytherapy Market is worth more than US$ 892.9 million at present.
The value of the Brachytherapy Market is projected to increase at a CAGR of around 8.3% from 2022 to 2032.
The value of the Brachytherapy Market increased at a CAGR of around 7.2% from 2017 to 2021.
Advanced solutions designed for specific requirements of cancer care facilities delivering financial, clinical, operational, and administrative services are bolstering the growth of the Brachytherapy Market.
Brachytherapy Market in China is projected to expand at a CAGR of around 9.9% from 2022 to 2032.
While the market in South Korea is expected to grow at nearly 5.7%, the market in Japan is projected to register a CAGR of nearly 7.4% from 2022 to 2032.
1. Executive Summary | Brachytherapy Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Product Life Cycle Analysis
3.5. Investment Feasibility Matrix
3.6. PESTLE and Porter’s Analysis
3.7. Regulatory Landscape 3.9.1. By Key Regions 3.9.2. By Key Countries
3.8. Regional Parent Market Outlook
4. Global Market Analysis 2017-2021 and Forecast, 2022-2032
4.1. Historical Market Size Value (US$ million) Analysis, 2017-2021
4.2. Current and Future Market Size Value (US$ million) Projections, 2022-2032
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Product Type
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ million) Analysis By Product Type, 2017-2021
5.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Product Type, 2022-2032
5.3.1. Seeds
5.3.2. Applicators & Afterloaders
5.3.3. Electronic Brachytherapy
5.4. Y-o-Y Growth Trend Analysis By Product Type, 2017-2021
5.5. Absolute $ Opportunity Analysis By Product Type, 2022-2032
6. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Dosage Type
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ million) Analysis By Dosage Type, 2017-2021
6.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Dosage Type, 2022-2032
6.3.1. HDR Brachytherapy
6.3.2. LDR Brachytherapy
6.4. Y-o-Y Growth Trend Analysis By Dosage Type, 2017-2021
6.5. Absolute $ Opportunity Analysis By Dosage Type, 2022-2032
7. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Application
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ million) Analysis By Application, 2017-2021
7.3. Current and Future Market Size Value (US$ million) Analysis and Forecast By Application, 2022-2032
7.3.1. Prostate Cancer
7.3.2. Gynecological Cancer
7.3.3. Breast Cancer
7.3.4. Other Applications
7.4. Y-o-Y Growth Trend Analysis By Application, 2017-2021
7.5. Absolute $ Opportunity Analysis By Application, 2022-2032
8. Global Market Analysis 2017-2021 and Forecast 2022-2032, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ million) Analysis By Region, 2017-2021
8.3. Current Market Size Value (US$ million) Analysis and Forecast By Region, 2022-2032
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2017-2021 and Forecast 2022-2032, By Country
9.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2017-2021
9.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2022-2032
9.2.1. By Country
9.2.1.1. the USA
9.2.1.2. Canada
9.2.2. By Product Type
9.2.3. By Dosage Type
9.2.4. By Application
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Product Type
9.3.3. By Dosage Type
9.3.4. By Application
9.4. Key Takeaways
10. Latin America Market Analysis 2017-2021 and Forecast 2022-2032, By Country
10.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2017-2021
10.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2022-2032
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Product Type
10.2.3. By Dosage Type
10.2.4. By Application
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Product Type
10.3.3. By Dosage Type
10.3.4. By Application
10.4. Key Takeaways
11. Europe Market Analysis 2017-2021 and Forecast 2022-2032, By Country
11.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2017-2021
11.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2022-2032
11.2.1. By Country
11.2.1.1. Germany
11.2.1.2. The United Kingdom
11.2.1.3. France
11.2.1.4. Spain
11.2.1.5. Italy
11.2.1.6. Russia
11.2.1.7. Rest of Europe
11.2.2. By Product Type
11.2.3. By Dosage Type
11.2.4. By Application
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Product Type
11.3.3. By Dosage Type
11.3.4. By Application
11.4. Key Takeaways
12. Asia Pacific Market Analysis 2017-2021 and Forecast 2022-2032, By Country
12.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2017-2021
12.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2022-2032
12.2.1. By Country
12.2.1.1. China
12.2.1.2. Japan
12.2.1.3. India
12.2.1.4. South Korea
12.2.1.5. Australia
12.2.1.6. Rest of APAC
12.2.2. By Product Type
12.2.3. By Dosage Type
12.2.4. By Application
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Product Type
12.3.3. By Dosage Type
12.3.4. By Application
12.4. Key Takeaways
13. Middle East and Africa Market Analysis 2017-2021 and Forecast 2022-2032, By Country
13.1. Historical Market Size Value (US$ million) Trend Analysis By Market Taxonomy, 2017-2021
13.2. Market Size Value (US$ million) Forecast By Market Taxonomy, 2022-2032
13.2.1. By Country
13.2.1.1. South Africa
13.2.1.2. Saudi Arabia
13.2.1.3. UAE
13.2.1.4. Israel
13.2.1.5. Rest of MEA
13.2.2. By Product Type
13.2.3. By Dosage Type
13.2.4. By Application
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Product Type
13.3.3. By Dosage Type
13.3.4. By Application
13.4. Key Takeaways
14. Key Countries Market Analysis
14.1. The USA
14.1.1. Pricing Analysis
14.1.2. Market Share Analysis, 2021
14.1.2.1. By Product Type
14.1.2.2. By Dosage Type
14.1.2.3. By Application
14.2. Canada
14.2.1. Pricing Analysis
14.2.2. Market Share Analysis, 2021
14.2.2.1. By Product Type
14.2.2.2. By Dosage Type
14.2.2.3. By Application
14.3. Brazil
14.3.1. Pricing Analysis
14.3.2. Market Share Analysis, 2021
14.3.2.1. By Product Type
14.3.2.2. By Dosage Type
14.3.2.3. By Application
14.4. Mexico
14.4.1. Pricing Analysis
14.4.2. Market Share Analysis, 2021
14.4.2.1. By Product Type
14.4.2.2. By Dosage Type
14.4.2.3. By Application
14.5. Germany
14.5.1. Pricing Analysis
14.5.2. Market Share Analysis, 2021
14.5.2.1. By Product Type
14.5.2.2. By Dosage Type
14.5.2.3. By Application
14.6. The United Kingdom
14.6.1. Pricing Analysis
14.6.2. Market Share Analysis, 2021
14.6.2.1. By Product Type
14.6.2.2. By Dosage Type
14.6.2.3. By Application
14.7. France
14.7.1. Pricing Analysis
14.7.2. Market Share Analysis, 2021
14.7.2.1. By Product Type
14.7.2.2. By Dosage Type
14.7.2.3. By Application
14.8. Spain
14.8.1. Pricing Analysis
14.8.2. Market Share Analysis, 2021
14.8.2.1. By Product Type
14.8.2.2. By Dosage Type
14.8.2.3. By Application
14.9. Italy
14.9.1. Pricing Analysis
14.9.2. Market Share Analysis, 2021
14.9.2.1. By Product Type
14.9.2.2. By Dosage Type
14.9.2.3. By Application
14.10. Russia
14.10.1. Pricing Analysis
14.10.2. Market Share Analysis, 2021
14.10.2.1. By Product Type
14.10.2.2. By Dosage Type
14.10.2.3. By Application
14.11. China
14.11.1. Pricing Analysis
14.11.2. Market Share Analysis, 2021
14.11.2.1. By Product Type
14.11.2.2. By Dosage Type
14.11.2.3. By Application
14.12. Japan
14.12.1. Pricing Analysis
14.12.2. Market Share Analysis, 2021
14.12.2.1. By Product Type
14.12.2.2. By Dosage Type
14.12.2.3. By Application
14.13. India
14.13.1. Pricing Analysis
14.13.2. Market Share Analysis, 2021
14.13.2.1. By Product Type
14.13.2.2. By Dosage Type
14.13.2.3. By Application
14.14. South Korea
14.14.1. Pricing Analysis
14.14.2. Market Share Analysis, 2021
14.14.2.1. By Product Type
14.14.2.2. By Dosage Type
14.14.2.3. By Application
14.15. Australia
14.15.1. Pricing Analysis
14.15.2. Market Share Analysis, 2021
14.15.2.1. By Product Type
14.15.2.2. By Dosage Type
14.15.2.3. By Application
14.16. South Africa
14.16.1. Pricing Analysis
14.16.2. Market Share Analysis, 2021
14.16.2.1. By Product Type
14.16.2.2. By Dosage Type
14.16.2.3. By Application
14.17. Saudi Arabia
14.17.1. Pricing Analysis
14.17.2. Market Share Analysis, 2021
14.17.2.1. By Product Type
14.17.2.2. By Dosage Type
14.17.2.3. By Application
14.18. UAE
14.18.1. Pricing Analysis
14.18.2. Market Share Analysis, 2021
14.18.2.1. By Product Type
14.18.2.2. By Dosage Type
14.18.2.3. By Application
14.19. Israel
14.19.1. Pricing Analysis
14.19.2. Market Share Analysis, 2021
14.19.2.1. By Product Type
14.19.2.2. By Dosage Type
14.19.2.3. By Application
15. Market Structure Analysis
15.1. Competition Dashboard
15.2. Competition Benchmarking
15.3. Market Share Analysis of Top Players
15.3.1. By Regional
15.3.2. By Product Type
15.3.3. By Dosage Type
15.3.4. By Application
16. Competition Analysis
16.1. Competition Deep Dive
16.1.1. Eckert & Ziegler
16.1.1.1. Overview
16.1.1.2. Product Portfolio
16.1.1.3. Profitability by Market Segments
16.1.1.4. Sales Footprint
16.1.1.5. Strategy Overview
16.1.1.5.1. Marketing Strategy
16.1.2. IsoRay Medical, Inc.
16.1.2.1. Overview
16.1.2.2. Product Portfolio
16.1.2.3. Profitability by Market Segments
16.1.2.4. Sales Footprint
16.1.2.5. Strategy Overview
16.1.2.5.1. Marketing Strategy
16.1.3. Elekta AB
16.1.3.1. Overview
16.1.3.2. Product Portfolio
16.1.3.3. Profitability by Market Segments
16.1.3.4. Sales Footprint
16.1.3.5. Strategy Overview
16.1.3.5.1. Marketing Strategy
16.1.4. Theragenics Corporation
16.1.4.1. Overview
16.1.4.2. Product Portfolio
16.1.4.3. Profitability by Market Segments
16.1.4.4. Sales Footprint
16.1.4.5. Strategy Overview
16.1.4.5.1. Marketing Strategy
16.1.5. Becton, Dickinson and Company
16.1.5.1. Overview
16.1.5.2. Product Portfolio
16.1.5.3. Profitability by Market Segments
16.1.5.4. Sales Footprint
16.1.5.5. Strategy Overview
16.1.5.5.1. Marketing Strategy
16.1.6. CIVCO Medical Solutions
16.1.6.1. Overview
16.1.6.2. Product Portfolio
16.1.6.3. Profitability by Market Segments
16.1.6.4. Sales Footprint
16.1.6.5. Strategy Overview
16.1.6.5.1. Marketing Strategy
16.1.7. Sun Nuclear Corporation
16.1.7.1. Overview
16.1.7.2. Product Portfolio
16.1.7.3. Profitability by Market Segments
16.1.7.4. Sales Footprint
16.1.7.5. Strategy Overview
16.1.7.5.1. Marketing Strategy
16.1.8. ICAD, Inc.
16.1.8.1. Overview
16.1.8.2. Product Portfolio
16.1.8.3. Profitability by Market Segments
16.1.8.4. Sales Footprint
16.1.8.5. Strategy Overview
16.1.8.5.1. Marketing Strategy
16.1.9. Varian Medical Systems, Inc.
16.1.9.1. Overview
16.1.9.2. Product Portfolio
16.1.9.3. Profitability by Market Segments
16.1.9.4. Sales Footprint
16.1.9.5. Strategy Overview
16.1.9.5.1. Marketing Strategy
17. Assumptions & Acronyms Used
18. Research Methodology
Explore Healthcare Insights
View Reports
Brachytherapy Market
